focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bizarre that today, if you look at ADV site, says 3 sells, yet up 2.2%! I reckon both the 40 & 50ks are buys, so one of those has to be yours Laura.
I have no idea why you could not buy more, maybe change your broker?
I purchased a small amount more and then Hargreaves wouldn't let me buy any more , it said there wasn't a quote available?
Thanks Kidlington
I am with Hargreaves so not sure what's its like with others.
I will do as you suggested and try less than the 250,000
Probably NT (Negotiated Trade)
Always happens.
Try buying a smaller amount? Maybe 2 x 100k and 1 x50k and you may get the amount required and the price could be less than 2.50p
Can anyone help me please
I'm trying to buy 250,000 shares but they won't let me buy at 2.5p
Does anyone known why?
Wonder if we get a RNS in the next day or so saying they are going to #SITC22, much like the did with last conference @ BioEurope in Leipzig. Personally, hope we dont, as its a waste of money and the info already put out on twitter.
I don't mind personally if these meetings then lead to ever nore contracts
Conferences are worth the expense of a few thousand to then gain new clients /contracts
Must be the largest "squad" going to a conference since CV19, or if ever at all?
Lets hope they are traveling economy class.
Nearly full squad attending.
https://twitter.com/Physiomics/status/1585547576216256512?s=20&t=uQ0h5aYJ6YfmkXczuHV_2g
Bit odd these lowish sells last 20 mins.
Doubt it L.
PYC relationship with CRUK is with Aleta and blood cancers.
We have a long standing relationship with Merckgroup, and a part of that is to do with DNA damage, which i believe is a different field to the article. The article is ICR lead, and our relationship with them is via Bicycle.
Does anyone know if this could be linked to PYC /CRUK relationship?
Trevor Graham, director of the Centre for Evolution and Cancer at The Institute of Cancer Research in London, said: "We've unveiled an extra level of control for how cancers behave - something we liken to cancer's 'dark matter'."
He told the BBC that there can be "tangles in lines of DNA" as they fold up in each cell and this can change which genes are read.
The position of the tangles can be very important in determining how cancers behave, he added.
"It's not going to change clinical care tomorrow but could be an avenue for developing new therapies," Prof Graham said.
Genetic testing for cancer mutations, such as BRCA which increases the risk of breast cancer, for example, only offers part of the picture about someone's cancer.
"By testing for both genetic and epigenetic changes, we could, potentially, much more accurately predict which treatments will work best for a particular person's cancer," Prof Graham said.
The findings are published in two papers in Nature - the first analysed more than 1,300 samples from 30 bowel cancers, showing that epigenetic changes were very common in cancerous cells and helped them grow more than other cells.
The second paper looked at lots of samples taken from different parts of the same tumour. It found that the way cancer cells develop is often governed by factors other than DNA mutations.
The researchers say their findings cannot prove that epigenetic changes directly lead to alterations in the way cancers behave, and more work needs to be done to show this occurs.
Got £4100 more and hope to add more with dividends from TSCO and LLOYD
Thabkyou Kidlington and Ralph
I am also invested in SCLP and their Rns shows how much money bio techs are prepared to spend on drug development
I am convinced PYC will continue to attract the larger clients who want to streamline their phase 1 to phase 3 pipelines
https://www.physiomics.co.uk/conference-presentation-4/
JM attending by looks of it.
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”), being held on 8-12 November 2022 in Boston, USA.
The Company will be presenting an original poster on the preclinical PK/PD relationship for NM32-2668 (“NM32”), a ROR1 targeting T cell engager. Physiomics is co-authoring the poster with client Numab Therapeutics whose investigational drug NM32 is currently in IND-enabling studies. NM32 is a tri-specific anti-ROR1/CD3/HSA antibody based on Numab’s scMATCH3 format which induces T cell-mediated lysis of tumours expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).
The poster (Abstract #1293) will be presented on 10 November from 0900-1900 EST, with the presenting authors attending at lunch (1140-1310) and during the poster reception (1930–2100). A copy of the poster will be made available on Physiomics’ website at 0900 EST (1400 BST) on the same day at: https://www.physiomics.co.uk/resources.
The Company will have substantial presence at the conference comprising both scientific and business development team members and will also host a stand in the main conference meeting hall (booth #236). If you’d like to meet the team at our booth please just drop by or use this link to book a meeting: https://www.physiomics.co.uk/sitc-2022/.
SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy through its initiatives, educational sessions, and collaborative endeavours. More information about the conference may be found using the following link: https://www.sitcancer.org/2022/home.
Dr Jim Millen, CEO said: “It’s great to be able to attend high profile conferences such as SITC in person again, and a privilege to be presenting important new work there. The team and I look forward to meeting existing clients attending SITC as well as those based in the Boston area and are excited at the prospect of discussions with potential new clients also!”
First day, quite a few people there, no pics of Hayley Close so far.
https://mobile.twitter.com/hashtag/bioeurope
Oi, can you get my name right over on t'other site?
BTW i bought most of my 900k at 1-2p, so pls get ones facts right old bean.
Tar muchly.
Hi Kidlington
That would be good....
Nice piece of news from VAL today.
Due to our connections with them, a seat on the SAB and connection with Kings college, wonder if we get any work from this new Cytolytix venture, CLX001
This was an excellent summary from another poster who had spoken to the comapny about the results
It clearly shows the excellent cash position
1 Company is very pleased with growth and this will continue into 2022- 2023
2) Company increased losses all due to pre planned new job roles. Cash runway very Conservative.. prob much more
3) They expect news shortly on the personalised medicine and non- core business (very interesting)
4) When It was mentioned that there was a confusion between "biggest pipeline " yet no RNS contracts since Servier they explained that they've been continuing to win new business but often the contracts are from clients who aren't yet ready to publicly state (Obviously Numab RNS came in yesterday also)
5) Was said that investors want more communications and the company / broker will make this a focus
6) Broker says Oncology spend will continue to grow and company says it is not impacted by current economic issues
7) They mentioned that a tweet from Bicycle is important as the person mentioned "is a real fan of PYC"
8) New business development person appointed last month is a big hitter and he used to work with Board member at a previous company and he is really helping PYC fine tune their offerings.
Oh dear i hate raw fish.
Last raise was in 2020.
Cash for 2 years.
I am the biggest critic of this firm, and yes heavily invested.
They are going to be in Boston USA at a conference highlighting their work with Numab. We now know what they are/were working on.
Like the RNS earlier this month when they said they were going to a BIO Europe, that appears to be a waste of money on a RNS, when they already tweeted it ( yes, a diff audience ) If they RNS the Boston visit, i'll be livid.
A very odd first post on here
And wrong on every point
How can there be more dilution when they've clearly stated they have enough cash for 2-3yrs
I would refer back to previous RNS
The company pays more on wages than it does for the cash for contracts. This has always been non-profit making. Despite these contracts won, it does not transfer to profits. This is essentially a charity funding by the gullible who buy their confetti. More and more funding to keep this going. Sooner or later shareholders must say no more cash. Then its curtains.
The contracts it wins does not cover salaries. This business just keeps a few boffins in work and is not a viable company in the real world without the kindness (or stupidity) of Pi to keep throwing money at it.
There is no real business here. Its a charity. No returns from this outfit. It all one way. From Pi to the Bosses and a workers who play on computers. No matter how many contracts it wins the boffins can only do so much.
History of dilutions and more are planned. Why buy these shares? Its a strong sell....
To where we were pre last RNS. huff.